Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Cardinal Health (CAH) said that the U.S. Food and Drug Administration has approved Lymphoseek (technetium Tc 99m tilmanocept) injection for pediatric use. Lymphoseek is radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsies or SLNB.


RTTNews | Jun 10, 2021 07:40AM EDT

07:39 Thursday, June 10, 2021 (RTTNews.com) - Cardinal Health (CAH) said that the U.S. Food and Drug Administration has approved Lymphoseek (technetium Tc 99m tilmanocept) injection for pediatric use. Lymphoseek is radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsies or SLNB.

In addition to adult use, the new indication will provide lymph node identification in pediatric patients with melanoma, rhabdomyosarcoma or other types of solid tumors. This will offer physicians, oncologists and nuclear medicine specialists an efficient, accurate and safe option to enhance lymphatic mapping and SLNB in pediatric melanoma cases, the most common skin cancer in children.

Read the original article on RTTNews ( https://www.rttnews.com/3201417/cardinal-health-gets-fda-approval-for-lymphoseek-pediatric-indication.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC